This study summarized a series of gene mutations, including tumor protein p53 (TP53), nucleophosmin, fms-related receptor tyrosine kinase 3, and CCAAT enhancer binding protein alpha, that may serve as potential prognostic markers and targets for AML [6, 7]. The gene discussed is TP53; the disease is acute myeloid leukemia.